Pharmadrug Stock Performance
| LMLLF Stock | USD 0.01 0.0006 5.83% |
The company holds a Beta of -3.78, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Pharmadrug are expected to decrease by larger amounts. On the other hand, during market turmoil, Pharmadrug is expected to outperform it. Pharmadrug right now holds a risk of 15.15%. Please check Pharmadrug potential upside, rate of daily change, and the relationship between the sortino ratio and skewness , to decide if Pharmadrug will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Pharmadrug has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly fragile essential indicators, Pharmadrug may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
| Begin Period Cash Flow | 2.1 M |
Pharmadrug |
Pharmadrug Relative Risk vs. Return Landscape
If you would invest 2.02 in Pharmadrug on August 29, 2024 and sell it today you would lose (0.93) from holding Pharmadrug or give up 46.04% of portfolio value over 90 days. Pharmadrug is currently producing 0.1823% returns and takes up 15.1456% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Pharmadrug, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Pharmadrug Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pharmadrug's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Pharmadrug, and traders can use it to determine the average amount a Pharmadrug's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.012
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LMLLF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 15.15 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.18 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pharmadrug is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pharmadrug by adding Pharmadrug to a well-diversified portfolio.
Pharmadrug Fundamentals Growth
Pharmadrug Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Pharmadrug, and Pharmadrug fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pharmadrug Pink Sheet performance.
| Return On Equity | -0.59 | |||
| Return On Asset | -0.19 | |||
| Operating Margin | (10.08) % | |||
| Current Valuation | 4.43 M | |||
| Shares Outstanding | 355.63 M | |||
| Price To Book | 0.55 X | |||
| Price To Sales | 7.86 X | |||
| Revenue | 494.99 K | |||
| EBITDA | (5.27 M) | |||
| Cash And Equivalents | 126.38 K | |||
| Total Debt | 786.37 K | |||
| Debt To Equity | 0.08 % | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (4.13 M) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 19.52 M | |||
About Pharmadrug Performance
By analyzing Pharmadrug's fundamental ratios, stakeholders can gain valuable insights into Pharmadrug's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pharmadrug has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pharmadrug has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Pharmadrug Inc. operates as a specialty pharmaceutical company. The company was formerly known as Aura Health Inc. and changed its name to Pharmadrug Inc. in October 2019. Pharmadrug operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.Things to note about Pharmadrug performance evaluation
Checking the ongoing alerts about Pharmadrug for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Pharmadrug help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pharmadrug had very high historical volatility over the last 90 days | |
| Pharmadrug has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 494.99 K. Net Loss for the year was (5.63 M) with profit before overhead, payroll, taxes, and interest of 182.04 K. | |
| Pharmadrug has accumulated about 126.38 K in cash with (4.13 M) of positive cash flow from operations. |
- Analyzing Pharmadrug's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pharmadrug's stock is overvalued or undervalued compared to its peers.
- Examining Pharmadrug's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pharmadrug's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pharmadrug's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pharmadrug's pink sheet. These opinions can provide insight into Pharmadrug's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pharmadrug Pink Sheet analysis
When running Pharmadrug's price analysis, check to measure Pharmadrug's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharmadrug is operating at the current time. Most of Pharmadrug's value examination focuses on studying past and present price action to predict the probability of Pharmadrug's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharmadrug's price. Additionally, you may evaluate how the addition of Pharmadrug to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stocks Directory Find actively traded stocks across global markets |